Active substance
Frovatriptan
- US FDA 6
- Health Canada 5
- US price lines 1
- NHS prices 1
- Safety 1
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| FROVATRIPTAN SUCCINATE | EQ 2.5MG BASE | tablet · oral | GLENMARK PHARMS LTD | Prescription | 11 Mar 2016 |
| FROVATRIPTAN SUCCINATE | EQ 2.5MG BASE | tablet · oral | AMNEAL PHARMS CO | Prescription | 6 Nov 2018 |
| FROVATRIPTAN SUCCINATE | EQ 2.5MG BASE | tablet · oral | RENATA | Prescription | 6 Apr 2022 |
| FROVATRIPTAN SUCCINATE | EQ 2.5MG BASE | tablet · oral | LEADING | Prescription | 16 Apr 2025 |
| FROVA | EQ 2.5MG BASE | tablet · oral | ENDO OPERATIONS | Discontinued | 8 Nov 2001 |
| FROVATRIPTAN SUCCINATE | EQ 2.5MG BASE | tablet · oral | PHARMOBEDIENT | Discontinued | 28 Aug 2014 |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| APO-FROVATRIPTAN | 02426471 | 2.5 MG | TABLET · ORAL | APOTEX INC |
| FROVA | 02257084 | 2.5 MG | TABLET · ORAL | KNIGHT THERAPEUTICS INC. |
| FROVATRIPTAN | 02535475 | 2.5 MG | TABLET · ORAL | SANIS HEALTH INC |
| JAMP FROVATRIPTAN | 02497131 | 2.5 MG | TABLET · ORAL | JAMP PHARMA CORPORATION |
| MINT-FROVATRIPTAN | 02509687 | 2.5 MG | TABLET · ORAL | MINT PHARMACEUTICALS INC |
Prices — United States and England
| Source | Product as listed | Price | Unit / pack | Date |
|---|---|---|---|---|
| US NADAC | FROVATRIPTAN SUCC 2.5 MG TAB | $2.71707 | per EA | 23 Sep 2026 |
| NHS Drug Tariff | Frovatriptan 2.5mg tablets | £2.79 | 6 tablet | 1 Oct 2026 |
NADAC: average price US retail pharmacies pay to buy the medicine. NHS Drug Tariff Part VIIIA: basic price reimbursed to pharmacies in England and Wales.
Safety signals and safety-related labeling changes
- US FDA 20 Aug 2018 FROVA — safety-related labeling change
Labeling sections changed: Use in Specific Populations; Patient Counseling Information / Patient Information / Medication Guide
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.